This platform provides Research Use Only (RUO) biochemical materials. By proceeding, you confirm and attest the following:
Research Use Only · Not for human consumption · Not FDA evaluated
We use cookies to remember your theme, age verification, and cart — and to understand how visitors use our site. By continuing, you agree to our use of cookies. See our Privacy Policy.
Dual Agonist GLP2
Dual GLP-1 and GIP receptor agonist studied for appetite control, blood sugar regulation, and significant weight loss. In clinical research, it has produced average weight loss of up to about 20% of body weight, more than single GLP-1 agonists.
Analytical Profile
Dual Agonist GLP2 is a research peptide that activates both the GLP-1 and GIP receptors, making it a dual incretin agonist. It is studied mainly for its effects on appetite regulation, blood sugar control, and significant body weight reduction. Through the GLP-1 pathway, Dual Agonist GLP2 helps reduce food noise, slow gastric emptying, and improve satiety. GIP receptor activation is believed to enhance insulin sensitivity and improve how the body handles and stores fat. In clinical research, it has produced substantial weight loss, averaging about 20% of body weight at the highest studied dose in the SURMOUNT-1 trial. That is greater than single GLP-1 agonists such as Single Agonist GLP1, which makes it a compound of high interest for metabolic, insulin resistance, and obesity-related studies.
Certificate of Analysis
Vendor Report — provided by the manufacturer for transparency. Independent in-house verification testing is in progress and will be added here when complete.